10-Q: Stereotaxis Reports Q1 2025 Results: Revenue Up, Losses Persist Amidst Tariff Concerns

Stereotaxis saw a revenue increase in Q1 2025, but continues to operate at a loss, with potential tariff implications looming.

Summary

• Stereotaxis, Inc. reported its financial results for the first quarter of 2025.
• Revenue increased by 9% to $7.5 million, compared to $6.9 million in Q1 2024.
• The company experienced a net loss of $5.8 million, compared to a net loss of $4.5 million in the same period last year.
• The loss attributable to common stockholders was $6.1 million, or $0.07 per share, compared to $4.8 million, or $0.06 per share, in Q1 2024.
• The company is monitoring the impact of macroeconomic factors, including tariffs and supply chain disruptions.
• The company believes its existing cash and cash equivalents will be sufficient to fund operations for the next twelve months, but additional funding may be needed.
• The company is exploring financing alternatives, including the sale of equity securities or non-core assets.
• The company completed the acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024.
• The Stereotaxis MAGiC catheter obtained CE marking in Europe during Q1 2025.
• The company is seeking FDA clearances for other devices, including the MAGiC Sweep catheter and the EMAGIN 5F catheter guide.

Sentiment

Score: 4

Explanation: The report shows revenue growth, but increased losses and concerns about tariffs and potential capital raises temper the positive aspects.

Positives

• Revenue increased by 9% to $7.5 million in Q1 2025.
• Revenue from disposables, service, and accessories increased by 29% to $5.5 million.
• The Stereotaxis MAGiC catheter received CE marking in Europe.
• The company is working towards FDA 510(k) regulatory clearance for the GenesisX RMN System in the United States.
• The company had $10.7 million of cash and cash equivalents as of March 31, 2025.

Negatives

• The company experienced a net loss of $5.8 million in Q1 2025.
• Gross margin decreased to 54% from 58% due to changes in product mix.
• The company is managing potential impacts from tariffs and trade regulations.
• The company may need additional funding and is exploring financing alternatives.

Risks

• Uncertainties in macroeconomic and geopolitical factors could materially adversely impact future results of operations and liquidity.
• Periodic worldwide supply chain disruptions, including shortages and inflationary pressures, tariffs and other trade regulations that are or may be imposed, and logistics delays could impact the company.
• Disruptions to the capital markets could negatively impact the company's ability to raise capital.
• The COVID-19 pandemic or similar occurrences may negatively affect demand for both systems and disposable products.
• The company may be unable to raise the prices of its products sufficiently to keep up with the rate of inflation, especially tariff induced inflation.
• The company is still integrating the businesses and implementing safeguards to minimize any negative impacts on our financial position, results of operations and cash flows post-acquisition.
• The company has generated significant losses since its inception and expects to incur additional losses in 2025.

Future Outlook

The company plans to advance adoption of its robotic magnetic navigation systems and proprietary devices in markets where regulatory clearance has been received and to work with regulatory approval authorities in geographies where approval is pending, with the goal of furthering clinical adoption and new system placements; the company expects to incur additional losses in 2025 as it continues the development and commercialization of its products, conducts research and development activities, advances new products into clinical development from existing research programs, and funds additional sales and marketing initiatives.

Industry Context

The company operates in the cardiac ablation market, which is a multi-billion-dollar medical device market with expectations for substantial long-term growth; the company is expanding the clinical focus of its technology to additional endovascular indications including coronary, neuro, and peripheral interventions.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards or benchmarks.
• Without specific comparable companies or projects mentioned, a detailed assessment against global benchmarks is not possible.

Legal Proceedings

• In February 2024, a vendor filed financing statements under the Uniform Commercial Code (UCC) on underlying inventory for approximately $0.6 million; the company believes the financing statements were filed without merit, and it is fully contesting the propriety of such actions.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and potential need for additional financing.
• Employees may be affected by potential delays in projects or reductions in resources.
• Customers may experience delays or disruptions due to supply chain issues or tariff impacts.
• Suppliers may be impacted by the company's efforts to diversify its supply chain or adjust contractual terms.

Next Steps

• Advance adoption of robotic magnetic navigation systems and proprietary devices in markets with regulatory clearance.
• Work with regulatory approval authorities in geographies where approval is pending.
• Continue development and commercialization of products.
• Conduct research and development activities.
• Advance new products into clinical development.
• Fund additional sales and marketing initiatives.
• Monitor the impact of the macroeconomic environment.
• Explore financing alternatives.

Key Dates

Keywords

Stereotaxis, Robotic Magnetic Navigation, Genesis RMN System, GenesisX RMN System, MAGiC catheter, Revenue, Net Loss, Tariffs, FDA Clearance, CE Marking, Acquisition, Access Point Technologies, Supply Chain, Financial Results, Q1 2025